Modulant

What Modulant does

Modulant, founded in 1989 and headquartered in N Charleston, South Carolina, is a private IT services and solutions firm employing between 51 and 100 people. Its functional focus spans four practice areas: Data Management, Systems Integration, Software Development, and IT Staffing, which collectively position it as a generalist integrator serving clients that need outsourced technology labor and bespoke software delivery. The firm does not publish its pricing or customer list, and revenue figures are not disclosed, consistent with a privately held, mid-sized services business operating largely on statement-of-work and staffing contracts.

Beyond its core IT services operations, Modulant operates a sub-brand, Modulant Biosciences, which holds a royalty-bearing license from PMGC Holdings' subsidiary Northstrive Biosciences for the worldwide development of two probiotic candidates (EL-22 and EL-32) in animal health applications. This biotech activity sits structurally and operationally apart from the parent's IT services base — the candidate is preclinical, with preliminary FDA feedback indicating EL-22 appears adequate to support a Phase 2 trial — and it represents a non-IT optionality rather than a current revenue driver.

The combined business model is therefore two-segment: a services-led core monetized through billable hours and project fees in Data Management, Systems Integration, Software Development, and IT Staffing, and a preclinical, royalty-licensed biotech optionality whose financial contribution is not yet material. Customer-specific information, contract economics, and GTM detail are not disclosed in available data, which constrains any granular underwriting of customer concentration or pricing power.

Name

Modulant

Legal name

Modulant Biosciences

Website

https://modulant.com

Company type

Private

Founded year

1989

Operating status

Operating

Headcount range

51–100 employees

Short description

Modulant is a private IT services firm (founded 1989, headquartered in N Charleston, US) providing Data Management, Systems Integration, Software Development, and IT Staffing services, with a biotech sub-brand, Modulant Biosciences, licensing probiotic candidates for worldwide animal health development.

Ownership category

akta.pro rank

Product category

Animal Health Biotechnology

NAICS

Research and Development in Biotechnology (except Nanobiotechnology) (541714), Biological Product (except Diagnostic) Manufacturing (325414)

SIC

Biological Products, (No Disgnostic Substances) (2836), Agricultural Prod-Livestock & Animal Specialties (200)

akta.pro industry

PRIMARYAFAJAKAE

Probiotics (Strains, Spore-Formers, Synbiotic Components)

Agriculture & Food Production/Food Ingredients & Additives/Nutraceutical & Functional Ingredients (Vitamins, Minerals, Omega-3s, Botanicals)

SECONDARYAFADAKAC

Probiotics, Prebiotics & Synbiotics

Agriculture & Food Production/Animal Feed Manufacturing/Medicated & Functional Feed (Coccidiostats, Probiotics, Performance Additives)

SECONDARYAFADAGAG

Probiotic/Direct-Fed Microbial (DFM) Premixes

Agriculture & Food Production/Animal Feed Manufacturing/Feed Premixes & Concentrates (Vitamins, Minerals, Additives)

Keywords

• Animal health biotechnology
• Probiotic therapeutics
• Biopharmaceutical licensing
• Veterinary drug development
• Clinical stage research

Headquarters

HQ city

N Charleston

HQ country

United States

HQ region

North America

Markets served

GTM type

B2B

Offering type

Services

Cost components

Technology or R&D, Personnel, Operations

Core offering

Modulant Biosciences is a biotechnology company developing probiotic and pharmaceutical candidates, including the EL-22 probiotic strain and the EL-32 compound, for animal health applications. The company holds a royalty-bearing licensing arrangement with Northstrive Biosciences (a PMGC Holdings subsidiary) for worldwide development and commercialization of these therapeutic candidates in the animal health sector.

Product overview

Based on the available source data, Modulant operates as a biotechnology company through its subsidiary Modulant Biosciences. The subsidiary is engaged in the development of probiotic candidates (EL-22) and related compounds (EL-32) for animal health applications through a worldwide licensing arrangement. However, the source data provides limited detail on the full product portfolio or architecture.

Differentiator

Problem solved

Functional benefit

Ideal customer profiles1 record

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Partnerships

One partnership is on record.

• PMGC Holdings Inc. (Northstrive Biosciences)coreStrategic or Co-development Partner · 1 January 2025PMGC Holdings executed a royalty-bearing license agreement with Modulant Biosciences for worldwide development of EL-22 and EL-32 in animal health applications. Northstrive Biosciences, the biopharmaceutical subsidiary of PMGC Holdings, received preliminary FDA feedback indicating its EL-22 probiotic candidate appears adequate to support a Phase 2 clinical trial. The licensing arrangement grants Northstrive Biosciences rights to develop and commercialize these therapeutic candidates in the animal health sector globally.

Recent moves3 records

Expansion highlights3 records

Broad incumbents

• Cargill Animal Nutrition: Cargill's animal nutrition business develops feed additives and gut-health solutions including probiotic ingredients. Comparable as a broad incumbent in animal probiotics and one of the dominant distribution channels Modulant would eventually need to access.
• ADM Animal Nutrition: ADM produces livestock feeds and feed additives including direct-fed microbials and probiotics. Comparable as a broad incumbent in the animal feed ingredient space and a natural channel partner for EL-22/EL-32 commercialization.
• Elanco Animal Health: Elanco is a major global animal health company with a portfolio that includes nutritional health products including probiotic-based solutions. It is comparable as a broad incumbent in the animal health space where Modulant is positioning EL-22 and EL-32.
• Zoetis: Zoetis is the world's largest animal health company developing therapeutics across species. Relevant as a broad incumbent whose diversified animal health portfolio overlaps with where Modulant's licensed candidates would compete.
• Novonesis (formerly Chr. Hansen + Novozymes): Novonesis is a global bioscience leader producing probiotic cultures and enzymes for animal nutrition, human health, and food applications. Comparable as a broad incumbent with deep capabilities in probiotic strain development for animal and human health end markets.

Direct peers

• Kemin Industries: Kemin manufactures feed additives, including probiotic-based solutions, for livestock and aquaculture. Directly comparable to Modulant's efforts to bring probiotic candidates into commercial animal health and nutrition channels.
• Lallemand Animal Nutrition: Lallemand is a leading developer and supplier of probiotic and yeast-based feed additives for livestock and companion animals. Directly comparable to Modulant's focus on probiotic candidates (EL-22, EL-32) for animal health applications.
• Adisseo: Adisseo is a global supplier of feed additives including probiotics and functional ingredients for animal nutrition. Comparable to Modulant for its focus on specialty feed ingredients serving animal health and performance.
• Phibro Animal Health: Phibro develops animal health products including nutritional specialty products and probiotics for livestock. Comparable to Modulant as an animal health-focused developer with similar target customers and regulatory pathways.

Emerging players

• Microbiome Therapeutics / Probionia (and similar clinical-stage veterinary probiotic developers): Emerging clinical-stage developers of microbiome-based therapeutics for veterinary use represent Modulant's nearest-stage peers. Comparable as smaller, science-driven entities advancing specific probiotic candidates through regulatory milestones, similar to Modulant's EL-22 progression toward Phase 2.

Market position

Strengths4 records

Weaknesses5 records

Competitive moat2 records

Key risks1 record

Key highlights6 records

Customer concentration

• Xx.com/Modulant1

Revenue estimate

Valuation estimate

Number of profiles

Profiles1 record

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Modulant